Search 

Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. We are committed problem solvers, redefining the meaning of customer service, with a focus on reducing time-to-market and minimising development costs.

A combination of scientific excellence, industry experience and a collaborative approach enable us to deliver high-quality innovative solutions, which allow our clients to succeed.

Our international team offers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory, which guide products efficiently from early development to marketing approval.

At Scottish Development International (SDI) we’re all about discovery: helping ambitious businesses like yours discover an exciting new chapter in Scotland. We’re here to help you discover new business opportunities, markets, ventures and people. And, most importantly, a pathway to success. How about discovering more about your business you never dreamed possible? From tech to fintech to chemical science and digital technology, we’ve helped over 5135 inward investors to realise their ambitions in Scotland. We’ll connect you with the right people. In the right place. And at the right time.

SEKISUI Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years. We continue to invest in new diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. We are a leading provider of rapid tests in the U.S., and high throughput coagulation systems in Japan. We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through direct sales, our commercial distribution networks and our partners.

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and
SLN124 to address beta-thalassaemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda.

Therakind, a private European pharmaceutical company, is focused on creating and developing safe, effective, authorised paediatric and speciality niche medicines. Our primary objective is to increase the availability of authorised paediatric and niche medicines and to ensure that the medication used today is both safe and effective.



Therakind's team has extensive experience in the paediatric pharmaceutical sector, we have the expertise to design clinical programmes and regulatory strategy to advance medicines from concept through to regulatory approval.



Therakind was pivotal in the process of bringing Buccolam®, a treatment for prolonged acute convulsive seizures, to the EU market. This product has been sold to Viropharma Inc (now Shire Pharmaceuticals) and is marketed across Europe.



Therakind is a private European pharmaceutical company established in 2006.

Tissue Solutions specializes in sourcing biological material for the global pharma & biotech industry. We are a virtual biobank, working with multiple sources to ethically acquire samples on behalf of our clients for use in preclinical research. We provide access to banked human tissues and set up prospective collections in the UK and USA. We specialise in sourcing difficult to access tissues, eg fresh samples or those with specific inclusion and exclusion criteria. We provide both diseased and non-diseased samples, FFPE and fresh frozen and fresh samples.

Vaccitech is a clinical stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. The company’s proprietary technology platform, comprising
Chimpanzee Adenovirus (prime) and MVA (boost) is exceptional at inducing, boosting and maintaining CD8+ and CD4+ T cells, as well as antibodies. The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford. Vaccitech currently has a Phase 2 clinical program for prostate cancer, a Phase 1 clinical program for chronic HBV and is poised to enter the clinic with HPV and NSCLC therapeutics. The company is also co-developing products for MERS coronavirus and Herpes Zoster with international collaborators and has outlicensed its rights to the ChAdOx COVID-19 vaccine being developed by the University of Oxford to AstraZeneca. Vaccitech is backed by leading institutions including GV, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.